Abbott India (500488) Q4 23/24 earnings summary

Executive summary

• Achieved revenue growth of 9.4% year-over-year, reaching ₹5,849 Crores for FY 2023-24.

• Net profit increased by 26.5% to ₹1,201 Crores compared to the previous year.

• EBITDA rose to ₹1,701 Crores, with a margin of 29.1%.

• Board recommended a final dividend of ₹410 per share, subject to AGM approval.

• Launched 8 new products across key therapeutic areas.

Financial highlights

• Revenue from operations: ₹5,849 Crores, up 9.4% year-over-year.

• Net profit: ₹1,201 Crores, up 26.5% year-over-year.

• EBITDA: ₹1,701 Crores, up 25.1% year-over-year.

• Earnings per share: ₹565.28, up 26.5% year-over-year.

• Return on average capital employed: 34.9%.

• Operating profit margin: 27.9%; net profit margin: 20.5%.

Outlook and guidance

• Focus on therapy shaping to accelerate growth of pillar brands and new launches.

• Continued investment in digital and omnichannel engagement.

• Plans to expand vaccine portfolio and adult vaccination market.

• Ongoing commitment to ESG goals and sustainability initiatives.